Competitive Edge | Discover how pegozafermin's unique benefits, including potential efficacy in cirrhotic MASH, position 89bio in the evolving treatment landscape |
Financial Outlook | Learn about 89bio's strong liquidity position and analyst projections, with price targets ranging from $12 to $58 per share |
Clinical Milestones | Delve into 89bio's ambitious Phase 3 trials, with key results expected from 2026 to 2028, potentially reshaping liver disease management |
MASH Market Pionee | Explore 89bio's pegozafermin, a promising FGF21 analog poised to revolutionize metabolic dysfunction-associated steatohepatitis (MASH) treatment |
Metrics to compare | ETNB | Peers Peers - average of corresponding metrics from companies closely matching ETNB: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipETNBPeersSector |
|---|---|---|---|---|
P/E Ratio | Unlock | NaN | NaN | Unlock |
PEG Ratio | Unlock | NaN | NaN | Unlock |
Price / Book | Unlock | NaN | NaN | Unlock |
Price / LTM Sales | Unlock | NaN | NaN | Unlock |
Upside (Analyst Target) | Unlock | NaN | NaN | Unlock |
Fair Value Upside | Unlock | NaN | NaN | Unlock |